Skip To Content

Resources

Biopharmaceuticals are structurally complex and pose numerous challenges in drug development. Globally, R&D companies are working to combat the complicated drug analysis necessary for large molecules, while trying to reduce laborious method development. Scientists at Merck have incorporated retention modeling into their strategy to simplify and accelerate their method development. Their method development strategy involves...

Analytical data is diverse, tied to many applications, and often difficult to access and share. But when data is managed well, the possibilities are endless. Here, three experts break down the key pain points and set you on the right path in your data management journey.

Natural products remain one of the major sources of coveted, biologically active compounds. Each isolated compound undergoes biological testing, and its structure is usually established using a set of spectroscopic techniques (NMR, MS, UV-IR, ECD, VCD, etc.). However, the number of erroneously determined structures remains noticeable. Structure revisions are very costly, as they usually require...

Graham McGibbon and Simon Meffan-Main (TetraScience) discuss the value of digital data and its huge potential to influence decision-making and experimentation.

Volume 31, issue 24 of Instrument Business Outlook (IBO) included Sales indexes for analytical instruments and sales in life sciences organizations as well as an overview of Pittcon. IBO spoke with ACD/Labs at the conference to ask about our latest product developments and differentiators. Below is an excerpt from their article. ACD/Labs’ knowledge management databases...

How ACD/Labs Enables More Robust, Efficient Separations With the increasingly challenging demands confronted by separation scientists on their expertise, resources, and time, traditional chromatography approaches are often lacking. Chromatographers require advanced informatics solutions that offer comprehensive coverage of all method development functions. Learn how ACD/Labs’ strategies enable compliance with Quality by Design (QbD) regulatory expectations,...

Developing safe medicines is hard work. Researchers must rigorously assess every drug candidate molecule to ensure it does not harm patients. Cardiotoxicity – toxicity to the heart – is one of the factors that scientists consider. Members of the ACD/Labs team, Kiril Lanevskij, Remigijus Didziapetris, and Andrius Sazonovas recently published a paper on the subject...

Structure Elucidator Suite was used to determine the structures of two enantiomers of dihydro-2-fluorodeschloroketamine (dihydro-2-FDCK), contributing to the findings of this article. These findings provide an important reference for analyzing other oxidative metabolites, laying the foundation for future analysis, prediction, elucidation and identification of the latest ketamine-type new psychoactive substance metabolites.